TrialDiabetes care2012

Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.

Irl B Hirsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.